Amedeo Smart

Free Medical Literature Service

 

Amedeo

Hypertension
  Free Subscription

Articles published in
Eur Heart J
    December 2025
  1. BIDEL Z, Nazarzadeh M, Canoy D, McEvoy JW, et al
    Blood pressure lowering in isolated diastolic hypertension and cardiovascular risk: an individual patient data meta-analysis.
    Eur Heart J. 2025 Dec 12:ehaf962. doi: 10.1093.
    >> Share

  2. VERDECCHIA P, Angeli F, Reboldi G
    Should systolic pressure be lowered in isolated diastolic hypertension?
    Eur Heart J. 2025 Dec 12:ehaf950. doi: 10.1093.
    >> Share


  3. Correction to: 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by th
    Eur Heart J. 2025;46:4949.
    >> Share

    November 2025
  4. CHEN X, Jilaihawi H, Wang Y
    One-stop pulmonary artery denervation and transcatheter tricuspid annuloplasty in combined pre- and post-capillary pulmonary hypertension with severe tricuspid regurgitation.
    Eur Heart J. 2025 Nov 28:ehaf934. doi: 10.1093.
    >> Share

  5. LIU R, Li H
    Adherence matters-even in young adults with hypertension.
    Eur Heart J. 2025 Nov 28:ehaf913. doi: 10.1093.
    >> Share

  6. NIELSEN ST, Luo J, Frikke-Schmidt R
    Genetic and methodological considerations in hypertensive disorders of pregnancy and risk of cardiovascular disease.
    Eur Heart J. 2025 Nov 25:ehaf933. doi: 10.1093.
    >> Share

  7. YAO BY, Su YZ, Zhang LY
    Overlooked complexities in pregnancy hypertension-cardiovascular disease genetic studies.
    Eur Heart J. 2025 Nov 25:ehaf931. doi: 10.1093.
    >> Share

  8. KELES M, Lawrie A
    Revisiting prostaglandin biology in pulmonary arterial hypertension: targeting the EP4/ANXA2 axis.
    Eur Heart J. 2025 Nov 19:ehaf871. doi: 10.1093.
    >> Share

  9. GALLO G, Volpe M
    Weekly Journal Scan: Targeting aldosterone synthase in uncontrolled and resistant hypertension.
    Eur Heart J. 2025 Nov 18:ehaf892. doi: 10.1093.
    >> Share

  10. WHITE SJ
    HEG1: a new protein linking endothelial dysfunction and hypertension.
    Eur Heart J. 2025 Nov 11:ehaf843. doi: 10.1093.
    >> Share

  11. FATIMA M, Sheikh S, Ammer Z
    Bridging The Gaps In EMPEROR-Preserved: Toward safer and smarter use of Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction.
    Eur Heart J. 2025 Nov 4:ehaf799. doi: 10.1093.
    >> Share

  12. TOKCAN M, Markwirth P, Bohm M
    Uniform benefits of empagliflozin across hypertension categories: a response.
    Eur Heart J. 2025 Nov 4:ehaf798. doi: 10.1093.
    >> Share

    October 2025
  13. PARIENTE A
    Pharmacoepidemiology as the delicate science of constructing robust plausibility where there is no certainty: the case for hypertension in young adults.
    Eur Heart J. 2025 Oct 17:ehaf712. doi: 10.1093.
    >> Share

  14. LI Y, Zheng J, Lu C, Fan F, et al
    Fractional flow reserve-guided renal artery stenting in atherosclerotic renovascular hypertension: the FAIR randomized trial.
    Eur Heart J. 2025 Oct 7:ehaf746. doi: 10.1093.
    >> Share

  15. VOLPE M, Guzik TJ, Messerli FH
    The need for a unified categorization of hypertension across guidelines.
    Eur Heart J. 2025 Oct 3:ehaf747. doi: 10.1093.
    >> Share

    September 2025
  16. XU H, Ye L, Du C, Tang H, et al
    EP4/ANXA2 axis in pulmonary arterial hypertension: therapeutic implications.
    Eur Heart J. 2025 Sep 25:ehaf763. doi: 10.1093.
    >> Share

  17. REA F, Morabito G, Corrao G, Mancia G, et al
    Antihypertensive treatment in young adults and cardiovascular risk: a population-based cohort study.
    Eur Heart J. 2025 Sep 25:ehaf744. doi: 10.1093.
    >> Share

  18. DEWLAND TA, van Dam RM, Marcus GM
    Coffee and cardiovascular disease.
    Eur Heart J. 2025;46:3546-3554.
    >> Share

  19. TAAGEBY NIELSEN S, Luo J, Tybjaerg-Hansen A, Iversen K, et al
    Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study.
    Eur Heart J. 2025 Sep 3:ehaf565. doi: 10.1093.
    >> Share

    August 2025
  20. AL-QAZAZI R, Emon IM, Potus F, Martin AY, et al
    Germline and somatic variants in DNMT3A and other clonal haematopoiesis of indeterminate potential genes contribute to pulmonary arterial hypertension.
    Eur Heart J. 2025 Aug 29:ehaf611. doi: 10.1093.
    >> Share

    July 2025
  21. CREA F
    Hot topics in prevention: resistant hypertension, blood pressure variability, triglycerides, and apoB-containing lipoproteins.
    Eur Heart J. 2025;46:2607-2610.
    >> Share

  22. GALLO G, Volpe M
    Weekly Journal Scan: BedMed cannot overcome the uncertainties on the effects of night-time antihypertensive therapy on cardiovascular outcomes.
    Eur Heart J. 2025 Jul 10:ehaf435. doi: 10.1093.
    >> Share

    June 2025
  23. CREA F
    Focus on juvenile hypertension, deep learning-qualified body composition for risk stratification, infective endocarditis, and mixed valvular heart disease.
    Eur Heart J. 2025;46:2249-2252.
    >> Share

  24. MENG Y, Koskinen JS, Thomson R, Juonala M, et al
    Blood pressure in childhood, young- and mid-adulthood: association with carotid plaque severity.
    Eur Heart J. 2025;46:2306-2316.
    >> Share

  25. CRUMP C, Sundquist J, Sundquist K
    Adverse pregnancy outcomes and long-term risk of stroke: a Swedish nationwide co-sibling study.
    Eur Heart J. 2025 Jun 23:ehaf366. doi: 10.1093.
    >> Share

  26. CHASELING GK, Uchmanowicz I, Back M, Miro O, et al
    Heat extremes and cardiovascular diseases: a scientific statement of the Association of Cardiovascular Nursing & Allied Professions, Association for Acute Cardiovascular Care, European Association of Preventive Cardiology, Heart Failure Association, E
    Eur Heart J. 2025 Jun 3:ehaf326. doi: 10.1093.
    >> Share

    May 2025
  27. PROCOPI N, Zeitouni M, Kerneis M, Cayla G, et al
    Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AbetaYSS trial.
    Eur Heart J. 2025 May 22:ehaf170. doi: 10.1093.
    >> Share

    April 2025
  28. SANIDAS E, Bohm M, Oikonomopoulou I, Dinopoulou P, et al
    Heart rate-lowering drugs and outcomes in hypertension and/or cardiovascular disease: a meta-analysis.
    Eur Heart J. 2025 Apr 25:ehaf291. doi: 10.1093.
    >> Share

  29. ZHANG DY, An DW, Yu YL, Melgarejo JD, et al
    Ambulatory blood pressure monitoring, European guideline targets, and cardiovascular outcomes: an individual patient data meta-analysis.
    Eur Heart J. 2025 Apr 18:ehaf220. doi: 10.1093.
    >> Share

  30. KOBAYASHI M, Pitt B, Ferreira JP, Rossignol P, et al
    Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease.
    Eur Heart J. 2025 Apr 11:ehaf225. doi: 10.1093.
    >> Share

  31. XIONG G
    Post-capillary pulmonary hypertension in heart failure: addressing statistical and methodological issues in research.
    Eur Heart J. 2025 Apr 8:ehae812. doi: 10.1093.
    >> Share

  32. FAUVEL C, Lamblin N
    Post-capillary Pulmonary Hypertension in Heart Failure is associated with higher mortality and morbidity risk: not just a matter of << hasard >>.
    Eur Heart J. 2025 Apr 8:ehae814. doi: 10.1093.
    >> Share

  33. CREA F
    Focus on blood pressure: sex-specific association with atrial fibrillation, role of gliflozins in hypertension, and new therapeutic targets in hypertension and orthostatic hypotension.
    Eur Heart J. 2025;46:1277-1280.
    >> Share

  34. WANG YL, Zhu H, Pan YT, Shang D, et al
    Dendritic cell mineralocorticoid receptor controls blood pressure by regulating T helper 17 differentiation: role of the Plcbeta1/4-Stat5-NF-kappaB pathway.
    Eur Heart J. 2025;46:1335-1351.
    >> Share

  35. LIN R, Fields JC, Lee R, Rosenfeld EB, et al
    Hospitalization for cardiovascular disease in the year after delivery of twin pregnancies.
    Eur Heart J. 2025;46:1219-1228.
    >> Share

    March 2025
  36. MESSERLI FH, Schoenenberger-Berzins R, Burnier M
    SGLT2 inhibitors: not for hypertension but exceedingly useful in hypertension.
    Eur Heart J. 2025 Mar 7:ehae751. doi: 10.1093.
    >> Share

  37. BOHM M, Butler J, Coats A, Lauder L, et al
    Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
    Eur Heart J. 2025 Mar 4:ehae938. doi: 10.1093.
    >> Share

    February 2025

  38. Correction to: 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by th
    Eur Heart J. 2025 Feb 11:ehaf031. doi: 10.1093.
    >> Share

    January 2025
  39. MIKOLAJCZYK TP, Sliwa T, Guzik TJ
    Immunometabolic switch in hypertension: how dendritic cell mineralocorticoid receptors drive Th17 polarization and blood pressure control.
    Eur Heart J. 2025 Jan 22:ehae863. doi: 10.1093.
    >> Share

  40. SHARASHOVA E, Gerdts E, Ball J, Schnabel RB, et al
    Long-term pulse pressure trajectories and risk of incident atrial fibrillation: the Tromso Study.
    Eur Heart J. 2025 Jan 17:ehaf005. doi: 10.1093.
    >> Share

    December 2024
  41. XIE D, Sun X, Cao Y
    Malignant pheochromocytoma associated with pulmonary hypertension.
    Eur Heart J. 2024 Dec 6:ehae842. doi: 10.1093.
    >> Share

  42. MIRZOYEV U
    Target 130/80: a future-focused initiative for hypertension management in Azerbaijan.
    Eur Heart J. 2024 Dec 3:ehae749. doi: 10.1093.
    >> Share

    October 2024
  43. LI Y, Gao F, Ren C, Ma G, et al
    The Netrod six-electrode radiofrequency renal denervation system for uncontrolled hypertension: a sham-controlled trial.
    Eur Heart J. 2024 Oct 21:ehae703. doi: 10.1093.
    >> Share

  44. MCCARTHY CP, Touyz RM, McEvoy JW
    The 'ten commandments' for the 2024 European Society of Cardiology guidelines on elevated blood pressure and hypertension.
    Eur Heart J. 2024 Oct 16:ehae646. doi: 10.1093.
    >> Share

  45. CREA F
    Focus on the European Society of Cardiology: Guidelines on hypertension, Atlas of cardiovascular disease statistics, and Consensus statement on obesity.
    Eur Heart J. 2024;45:3897-3900.
    >> Share

  46. KENNEDY C, Hayes P, Cicero AFG, Dobner S, et al
    Semaglutide and blood pressure: an individual patient data meta-analysis.
    Eur Heart J. 2024;45:4124-4134.
    >> Share

    September 2024
  47. OBIEZU-UMEH C, Huffman MD, Ojji DB
    Integration of a hypertension treatment programme into Nigeria's primary healthcare system: report from a stakeholders and policymakers' workshop.
    Eur Heart J. 2024 Sep 10:ehae376. doi: 10.1093.
    >> Share

  48. VERGALLO R, Volpe M
    Weekly Journal Scan: A large Chinese SPRINT supports 'the lower, the better' blood pressure in hypertensive patients at high cardiovascular risk.
    Eur Heart J. 2024 Sep 4:ehae531. doi: 10.1093.
    >> Share

  49. COHEN JB, Bress AP
    Quantifying antihypertensive effects of GLP-1 agonists.
    Eur Heart J. 2024 Sep 1:ehae520. doi: 10.1093.
    >> Share

    August 2024
  50. MCEVOY JW, McCarthy CP, Bruno RM, Brouwers S, et al
    2024 ESC Guidelines for the management of elevated blood pressure and hypertension.
    Eur Heart J. 2024 Aug 30:ehae178. doi: 10.1093.
    >> Share

  51. CREA F
    Expanding knowledge in atrial fibrillation, blood pressure treatment, and management of coronary and peripheral artery disease.
    Eur Heart J. 2024;45:2795-2799.
    >> Share

  52. BOHM M, de la Sierra A, Mahfoud F, Schwantke I, et al
    Office measurement vs. ambulatory blood pressure monitoring: associations with mortality in patients with or without diabetes.
    Eur Heart J. 2024;45:2851-2861.
    >> Share

  53. MANCIA G, Facchetti R, Grassi G
    Risk prediction by ambulatory blood pressure monitoring in non-diabetic and diabetic patients: better than office measurements.
    Eur Heart J. 2024;45:2862-2864.
    >> Share

  54. ROSENKRANZ S, Hoeper MM, Maron BA
    Pulmonary hypertension in heart failure: the good, the bad, and the ugly.
    Eur Heart J. 2024 Aug 12:ehae518. doi: 10.1093.
    >> Share

    July 2024
  55. FAUVEL C, Damy T, Berthelot E, Bauer F, et al
    Post-capillary pulmonary hypertension in heart failure: impact of current definition in the PH-HF multicentre study.
    Eur Heart J. 2024 Jul 26:ehae467. doi: 10.1093.
    >> Share

  56. ROGER G, Ducrocq G, Mesnier J, Sayah N, et al
    Chronic coronary syndromes without standard modifiable cardiovascular risk factors and outcomes: the CLARIFY registry.
    Eur Heart J. 2024;45:2396-2406.
    >> Share

    April 2024
  57. VERGALLO R, Volpe M
    Lowering dietary sodium intake to reduce blood pressure: cum grano salis.
    Eur Heart J. 2024;45:1301-1302.
    >> Share

    March 2024
  58. PITRE T, Weatherald J, Humbert M
    Treatments for pulmonary arterial hypertension: navigating through a network of choices.
    Eur Heart J. 2024 Mar 5:ehae106. doi: 10.1093.
    >> Share

  59. MA E, Wo D, Chen J, Yan H, et al
    Inhibition of a novel Dickkopf-1-LDL receptor-related proteins 5 and 6 axis prevents diabetic cardiomyopathy in mice.
    Eur Heart J. 2024;45:688-703.
    >> Share

    February 2024
  60. MOUTCHIA J, McClelland RL, Al-Naamani N, Appleby DH, et al
    Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis.
    Eur Heart J. 2024 Feb 28:ehae049. doi: 10.1093.
    >> Share

  61. RUILOPE LM, Ortiz A, Ruiz-Hurtado G
    Hypertension and the kidney: an update.
    Eur Heart J. 2024 Feb 8:ehad896. doi: 10.1093.
    >> Share

    January 2024
  62. GUPTA A, Whiteley WN, Godec T, Rostamian S, et al
    Legacy benefits of blood pressure treatment on cardiovascular events are primarily mediated by improved blood pressure variability: the ASCOT trial.
    Eur Heart J. 2024 Jan 31:ehad814. doi: 10.1093.
    >> Share

    December 2023
  63. TOTH PP
    Dickkopf-1: an emerging danger signal in hypertension and cardiovascular disease.
    Eur Heart J. 2023 Dec 29:ehad797. doi: 10.1093.
    >> Share

  64. HE Z, Zhang D, Wang X
    Fibrosing mediastinitis manifesting as refractory pleural effusion and severe pulmonary hypertension successfully treated by percutaneous pulmonary vein stenting.
    Eur Heart J. 2023 Dec 28:ehad862. doi: 10.1093.
    >> Share

  65. LI XM, Zhu XJ, Jing ZC
    Reverse cardiac remodelling after balloon atrial septostomy for pulmonary arterial hypertension and end-stage heart failure.
    Eur Heart J. 2023 Dec 16:ehad822. doi: 10.1093.
    >> Share

  66. O'DONNELL M, Yusuf S, Vogt L, Mente A, et al
    Potassium intake: the Cinderella electrolyte.
    Eur Heart J. 2023;44:4925-4934.
    >> Share

  67. SCHNEIDER SR, Muller J, Bauer M, Mayer L, et al
    Overnight exposure to high altitude in pulmonary hypertension: adverse events and effect of oxygen therapy.
    Eur Heart J. 2023 Dec 11:ehad789. doi: 10.1093.
    >> Share

    November 2023
  68. VOLPE M, Galiuto L
    More on aldosterone biosynthesis inhibition and resistant hypertension: a Phase-2 study with lorundrostat.
    Eur Heart J. 2023 Nov 9:ehad756. doi: 10.1093.
    >> Share

  69. TSCHIDERER L, van der Schouw YT, Burgess S, Bloemenkamp KW, et al
    Hypertensive disorders of pregnancy and cardiovascular disease risk: A Mendelian Randomisation study.
    Eur Heart J. 2023;44.
    >> Share

  70. GALIE N, Palazzini M, Manes A
    Confirmation of survival prediction based on 2022 ESC/ERS pulmonary hypertension guidelines new haemodynamic thresholds.
    Eur Heart J. 2023 Nov 7:ehad672. doi: 10.1093.
    >> Share

  71. ACKLAND GL, Patel A, Abbott TEF, Begum S, et al
    Discontinuation vs. continuation of renin-angiotensin system inhibition before non-cardiac surgery: the SPACE trial.
    Eur Heart J. 2023 Nov 7:ehad716. doi: 10.1093.
    >> Share

    October 2023
  72. BRAUNWALD E
    Inhibition of angiotensinogen in the treatment of hypertension.
    Eur Heart J. 2023 Oct 27:ehad704. doi: 10.1093.
    >> Share

    September 2023
  73. LIU JN, Zhao ZG, Luo FM
    Pulmonary hypertension-related dynamic left ventricular outflow tract obstruction.
    Eur Heart J. 2023 Sep 19:ehad605. doi: 10.1093.
    >> Share

  74. LIUZZO G, Volpe M
    Silencing liver angiotensinogen synthesis as a novel approach to hypertension management: promises and challenges.
    Eur Heart J. 2023 Sep 8:ehad593. doi: 10.1093.
    >> Share

    August 2023
  75. RAO S, Nazarzadeh M, Canoy D, Li Y, et al
    Sodium-based paracetamol: impact on blood pressure, cardiovascular events, and all-cause mortality.
    Eur Heart J. 2023 Aug 23:ehad535. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016